Experienced in Head and Neck Squamous Cell Carcinoma (HNSCC)

Dr. Benjamin Lockshin

Dermatology
DermAssociates Rockville
15245 Shady Grove Rd, 
Rockville, MD 

Experienced in Head and Neck Squamous Cell Carcinoma (HNSCC)
DermAssociates Rockville
15245 Shady Grove Rd, 
Rockville, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Benjamin Lockshin is a Dermatologist in Rockville, Maryland. Dr. Lockshin is rated as an Experienced provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Atopic Dermatitis, Psoriasis, Plaque Psoriasis, and Syringoma.

His clinical research consists of co-authoring 41 peer reviewed articles and participating in 21 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Dermatology
Licenses
Dermatology in MD
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Group Health Cooperative
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthKeepers
  • POS
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
PacificSource
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SelectHealth
  • HMO
  • POS
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Silversummit Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 26 Less Insurance Carriers -

Locations

DermAssociates Rockville
15245 Shady Grove Rd, Rockville, MD 20850
Call: 301-681-7397

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


16 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Pragmatic Trial of Home Versus Office Based Narrow Band Ultraviolet B Phototherapy for the Treatment of Psoriasis
A Pragmatic Trial of Home Versus Office Based Narrow Band Ultraviolet B Phototherapy for the Treatment of Psoriasis
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Device
Study Phase: Not Applicable
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 24, 2023
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase IV, Open Label Study of the Effects of Apremilast on Vascular Inflammation and Cardiometabolic Function in Psoriasis
A Phase IV, Open Label Study of the Effects of Apremilast on Vascular Inflammation and Cardiometabolic Function in Psoriasis
Enrollment Status: Completed
Publish Date: November 10, 2022
Intervention Type: Drug
Study Drug: Apremilast
Study Phase: Phase 4
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 09, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy and Safety of Lebrikizumab When Used In Combination With Topical Corticosteroid Treatment In Patients With Moderate-To-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy and Safety of Lebrikizumab When Used In Combination With Topical Corticosteroid Treatment In Patients With Moderate-To-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Other, Biological
Study Drugs: Lebrikizumab, Topical Corticosteroid
Study Phase: Phase 3
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: September 27, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 04, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3375880 in Adult Subjects With Moderate-to-Severe Atopic Dermatitis: The ADmIRe Study
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3375880 in Adult Subjects With Moderate-to-Severe Atopic Dermatitis: The ADmIRe Study
Enrollment Status: Terminated
Publish Date: April 20, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
Enrollment Status: Completed
Publish Date: March 30, 2021
Intervention Type: Drug
Study Phase: Phase 3
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Melanoma
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Melanoma
Enrollment Status: Terminated
Publish Date: February 10, 2021
Intervention Type: Other
MAP Study (Methotrexate and Adalimumab in Psoriasis): Adalimumab vs. Combination Adalimumab and Methotrexate in Psoriasis: Efficacy and Anti-Adalimumab Antibody Formation
MAP Study (Methotrexate and Adalimumab in Psoriasis): Adalimumab vs. Combination Adalimumab and Methotrexate in Psoriasis: Efficacy and Anti-Adalimumab Antibody Formation
Enrollment Status: Completed
Publish Date: July 09, 2019
Intervention Type: Drug, Biological
Study Phase: Phase 2/Phase 3
View 15 Less Clinical Trials

41 Total Publications

Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical Trial.
Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical Trial.
Journal: JAMA dermatology
Published: May 07, 2025
View All 41 Publications
Similar Doctors
Distinguished in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Richard Pfau
Dermatology
Distinguished in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Richard Pfau
Dermatology

Anne Arundel Dermatology-Pathology

7671 Quarterfield Rd Ste 200, 
Millersville, MD 
 (23.1 miles away)
443-351-3376
Languages Spoken:
English
See accepted insurances

Richard Pfau is a Dermatologist in Millersville, Maryland. Dr. Pfau is rated as a Distinguished provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Basal Cell Skin Cancer, Actinic Keratosis, Acanthosis Nigricans, and Squamous Cell Skin Carcinoma.

Distinguished in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Mark Eid
Dermatology
Distinguished in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Mark Eid
Dermatology

Office

1985 Emancipation Hwy, 
Fredericksburg, VA 
 (55.5 miles away)
540-373-6647
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mark Eid is a Dermatologist in Fredericksburg, Virginia. Dr. Eid is rated as a Distinguished provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Basal Cell Skin Cancer, Squamous Cell Skin Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), and Bowen's Disease.

Advanced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. David Mezebish
Dermatology
Advanced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. David Mezebish
Dermatology

Top PT

9711 Medical Center Dr Ste 307, 
Rockville, MD 
 (8.8 miles away)
240-453-0050
Languages Spoken:
English
See accepted insurances

David Mezebish is a Dermatologist in Rockville, Maryland. Dr. Mezebish is rated as an Advanced provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Squamous Cell Skin Carcinoma, Basal Cell Skin Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), and Syringoma.

VIEW MORE HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lockshin's expertise for a condition
ConditionClose
  • Elite
  • Atopic Dermatitis
    Dr. Lockshin is
    Elite
    . Learn about Atopic Dermatitis.
    See more Atopic Dermatitis experts
  • Distinguished
  • Plaque Psoriasis
    Dr. Lockshin is
    Distinguished
    . Learn about Plaque Psoriasis.
    See more Plaque Psoriasis experts
  • Psoriasis
    Dr. Lockshin is
    Distinguished
    . Learn about Psoriasis.
    See more Psoriasis experts
  • Syringoma
    Dr. Lockshin is
    Distinguished
    . Learn about Syringoma.
    See more Syringoma experts
  • Advanced
  • Actinic Keratosis
    Dr. Lockshin is
    Advanced
    . Learn about Actinic Keratosis.
    See more Actinic Keratosis experts
  • Cerebral Cavernous Malformation
    Dr. Lockshin is
    Advanced
    . Learn about Cerebral Cavernous Malformation.
    See more Cerebral Cavernous Malformation experts
  • Cherry Angioma
    Dr. Lockshin is
    Advanced
    . Learn about Cherry Angioma.
    See more Cherry Angioma experts
  • Contact Dermatitis
    Dr. Lockshin is
    Advanced
    . Learn about Contact Dermatitis.
    See more Contact Dermatitis experts
  • Dyschromatosis Symmetrica Hereditaria
    Dr. Lockshin is
    Advanced
    . Learn about Dyschromatosis Symmetrica Hereditaria.
    See more Dyschromatosis Symmetrica Hereditaria experts
  • Dyschromatosis Universalis Hereditaria
    Dr. Lockshin is
    Advanced
    . Learn about Dyschromatosis Universalis Hereditaria.
    See more Dyschromatosis Universalis Hereditaria experts
View All 19 Advanced Conditions
  • Experienced
  • Acrokeratoelastoidosis of Costa
    Dr. Lockshin is
    Experienced
    . Learn about Acrokeratoelastoidosis of Costa.
    See more Acrokeratoelastoidosis of Costa experts
  • Alopecia Areata
    Dr. Lockshin is
    Experienced
    . Learn about Alopecia Areata.
    See more Alopecia Areata experts
  • Athlete's Foot
    Dr. Lockshin is
    Experienced
    . Learn about Athlete's Foot.
    See more Athlete's Foot experts
  • Autoerythrocyte Sensitivity
    Dr. Lockshin is
    Experienced
    . Learn about Autoerythrocyte Sensitivity.
    See more Autoerythrocyte Sensitivity experts
  • Autosomal Recessive Cutis Laxa Type 1
    Dr. Lockshin is
    Experienced
    . Learn about Autosomal Recessive Cutis Laxa Type 1.
    See more Autosomal Recessive Cutis Laxa Type 1 experts
  • Autosomal Recessive Hypotrichosis
    Dr. Lockshin is
    Experienced
    . Learn about Autosomal Recessive Hypotrichosis.
    See more Autosomal Recessive Hypotrichosis experts
View All 70 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.